Related Experiment Videos
Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001
1Department of Cardiology, University of Vienna--General Hospital, Wahringer Gurtel 18-10, 1090, Vienna, Austria. kurt.huber@univie.ac.at
Insights
Plasminogen activator inhibitor type-1 (PAI-1) promotes thrombus formation and cardiovascular disease. Targeting PAI-1 with specific drugs or TNK-tPA may improve thrombolytic therapy efficacy for acute myocardial infarction.
Area of Science:
- Cardiovascular Medicine
- Thrombosis Research
- Pharmacology
Background:
- Plasminogen activator inhibitor type-1 (PAI-1) is implicated in thrombus formation and cardiovascular diseases.
- Elevated PAI-1 levels are linked to atherosclerosis risk factors like insulin resistance, diabetes, and hypertriglyceridemia.
- The activated renin-angiotensin-aldosterone system (RAAS) upregulates PAI-1 via receptor-mediated mechanisms.
Purpose of the Study:
- To explore the role of PAI-1 in cardiovascular disease and thrombolytic therapy.
- To discuss the impact of PAI-1 on acute myocardial infarction treatment failure.
- To review therapeutic strategies targeting PAI-1 to enhance fibrinolytic capacity.
Main Methods:
- Review of existing literature on PAI-1 regulation and its clinical implications.
- Analysis of the relationship between PAI-1 plasma levels and atherosclerosis risk factors.
- Examination of the effects of various drugs (antidiabetics, fibrates, statins, ACE inhibitors, ARBs) on PAI-1 levels.
- Discussion of TNK-tPA as a PAI-1 resistant therapeutic option.
Main Results:
- PAI-1 contributes to thrombus formation and cardiovascular disease progression.
- Elevated pretreatment PAI-1 levels are associated with failed thrombolytic therapy in acute myocardial infarction.
- Pharmacological agents targeting risk factors may downregulate PAI-1, increasing fibrinolytic capacity.
- TNK-tPA offers improved efficacy in thrombolytic therapy due to PAI-1 resistance.
Conclusions:
- PAI-1 plays a significant role in thrombotic and cardiovascular diseases.
- Modulating PAI-1 levels through pharmacotherapy can enhance fibrinolysis and counteract thrombosis.
- TNK-tPA represents a promising advancement for thrombolytic therapy in acute myocardial infarction.
Abstract:
Plasminogen activator inhibitor type-1 (PAI-1) is known to contribute to thrombus formation and to the development and the clinical course of acute and chronic cardiovascular disease, as well as of other arterial and venous thromboembolic diseases. Recently, an important role of elevated pretreatment levels of PAI-1 for failure of thrombolytic therapy of acute myocardial infarction has been discussed. PAI-1 plasma levels depend on the one hand on gene regulation but are related on the other hand to known risk factors of atherosclerosis like insulin resistance, diabetes or hypertriglyceridemia, respectively. Furthermore, an activated renin-angiotensin-aldosterone system (RAAS) significantly contributes to the upregulation of PAI-1 concentration via a receptor-mediated mechanism. In accordance to the known mechanisms of regulation of PAI-1 plasma levels, the use of specific agents like antidiabetic drugs, fibrates, statins, ACE inhibitors and angiotensin II type-1 receptor-blockers may contribute to the downregulation of circulating PAI-1 and, therefore, increase the fibrinolytic capacity and consecutively counteract the thrombotic tendency. To further improve the efficacy of thrombolytic therapy, a PAI-1 resistant variant of t-PA, TNK-t-PA, has been developed and is now available for acute myocardial infarction.